XFOR Stock Analysis: Buy, Sell, or Hold?
XFOR - X4 Pharmaceuticals, Inc. Common Stock
$4.00
-0.12 (-2.91%)
▼
5d:
-1.96%
30d:
-0.99%
90d:
-1.72%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When XFOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: XFOR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: XFOR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: XFOR is currently trading at $4.00, which is considered fair relative to its 30-day fair value range of $3.81 to $4.13.
Technical Outlook: Technically, XFOR is in a uptrend. Immediate support is located at $3.66, while resistance sits at $4.36.
Market Sentiment: XFOR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.75 (+193.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XFOR is in a uptrend. Immediate support is located at $3.66, while resistance sits at $4.36.
Market Sentiment: XFOR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.75 (+193.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.81 -
$4.13
Company Quality Score
61/100
(BUY)
Options IV Signal
20th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 20th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 193.8% below Wall St target ($11.75)
Trading Range Analysis
30-Day Trading Range
$3.81 -
$4.13
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.54
(13.4%)
Support & Resistance Levels
Support Level
$3.66
Resistance Level
$4.36
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.38
Wall Street Target
$11.75
(+193.8%)
Revenue Growth (YoY)
-90.6%
Share & Embed Analysis
Last updated: June 23, 2026 6:23 PM ET
Data refreshes hourly during market hours. Next update: 7:23 PM
Data refreshes hourly during market hours. Next update: 7:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XFOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |
